Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAPGlobeNewsWire · Oct 13, 2026
The Longview: Fireside Chat with Biodexa CEO Stephen StampAccesswire · Sep 23, 2026
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross ProceedsGlobeNewsWire · Sep 15, 2026
Interim results for the six months ended June 30, 2026GlobeNewsWire · Sep 11, 2026
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAPGlobeNewsWire · Aug 19, 2026
Result of General MeetingGlobeNewsWire · Jul 29, 2026Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers.